A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515744-23-00

Acronym

COVALENT-101

Enrollment

Registered

2024-10-08

Start date

2023-02-15

Completion date

2025-03-05

Last updated

2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory (R/R) Acute lymphoblastic leukemia (ALL), R/R Acute mixed-phenotype leukemia (AMPL), R/R Acute myeloid leukemia (AML), R/R Chronic lymphocytic leukemia (CLL), R/R Diffuse large B-cell lymphoma (DLBCL), R/R Small lymphocytic lymphoma (SLL)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Netherlands, Spain

Outcome results